Is intrapartum intravenous zidovudine for prevention of mother-to-child hiv-1 transmission still useful in the combination antiretroviral therapy era?

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 903-914

  Briand, Nelly ^a   Warszawski, Josiane ^a,b   Mandelbrot, Laurent ^a,c,d   Dollfus, Catherine ^e   Pannier, Emmanuelle ^f   Cravello, Ludovic ^g   Nguyen, Rose ^h   Matheron, Isabelle ⁱ   Winer, Norbert ^j   Tubiana, Roland ^k,l   Rouzioux, Christine ^c,m   Faye, Albert ^c,n   Blanche, Stéphane ^c,m  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f Service d'Hématologie et d'Oncologie Pédiatrique ^*  (France)

^g HÔPITAL DE LA CONCEPTION   (France)

^h CENTRE HOSPITALIER SUD FRANCILIEN   (France)

ⁱ Centre Hospitalier Intercommunal de Villeneuve Saint Georges   (France)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l INSERM   (France)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ HÔPITAL ROBERT DEBRÉ   (France)

more..

Author keywords

intrapartum prophylaxis; mother to child HIV transmission; pregnancy; toxicity; zidovudine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; COHORT ANALYSIS; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INTRAPARTUM CARE; MAJOR CLINICAL STUDY; MULTIPARA; NEUTROPENIA; NEWBORN; PERINATAL DRUG EXPOSURE; PREMATURITY; PRIORITY JOURNAL; SIDE EFFECT; VAGINAL DELIVERY; VERTICAL TRANSMISSION; VIRUS LOAD;

INTRAPARTUM PROPHYLAXIS; MOTHER-TO-CHILD HIV TRANSMISSION; PREGNANCY; TOXICITY; ZIDOVUDINE;

ADULT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 84883258080     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit374     Document Type: Article

References (32)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-94.
2. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudinezidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-93.
3. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-65.
4. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads 1000 copies/ml. J Infect Dis. 2001, 183, 539-45.
5. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-99.
6. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
7. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995; 142:1330-7.
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-80.
9. Dormont D. Prise en charge des personnes atteintes par le VIH. Paris: Secrétariat d'Etat à la santé et à la sécurité sociale, 1996.
10. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Paris: Ministere de la Santé et des Solidarités, 2010.
11. Panel on Treatment of HIV-Infected PregnantWomen and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2012.
12. AIDS Clinical Trials Group. Division of AIDS table for grading the severity of adult and pediatric adverse events. Rockville, MD: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, 2004.
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81.
14. Kwiatkowski F, Slim K, Verrelle P, Chamorey E, Kramar A. Propensity score: interest and limits [in French]. Bulletin du cancer 2007; 94:680-6.
15. Sturmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol 2005; 162:279-89.
16. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 2010; 29:1037-57.
17. Mayaux MJ, Teglas JP, Blanche S. Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr 2003; 34:338-43.
18. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG 2008; 115:1078-86.
19. European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353:1035-9.
20. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998; 280:55-60.
21. Newell ML, Parazzini F, Mandelbrot L, et al. A randomised trial of mode of delivery in women infected with the human immunodeficiency virus. Br J Obstet Gynaecol 1998; 105:281-5.
22. Kuhn L, Stein ZA. Mother-to-infant HIV transmission: timing, risk factors and prevention. Paediatr Perinat Epidemiol 1995; 9:1-29.
23. Bobat R, Coovadia H, Coutsoudis A, Moodley D. Determinants of mother-to-child transmission of human immunodeficiency virus type 1 infection in a cohort from Durban, South Africa. Pediatr Infect Dis J 1996; 15:604-10.
24. Mother-to-child transmission of human immunodeficiency virus in Italy: temporal trends and determinants of infection. The Italian Collaborative Study on HIV infection in pregnancy. Hum Reprod 1999; 14:242-6.
25. Grosch-Worner I, Schafer A, Obladen M, et al. An effective and safe protocol involving zidovudine and caesarean section to reduce vertical transmission of HIV-1 infection. AIDS 2000; 14:2903-11.
26. Italian Register for Human Immunodeficiency Virus Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med 2002; 156:915-21.
27. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340:977-87.
28. Chiappini E, Galli L, Giaquinto C, et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS 2013; 27:911-1000.
29. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, Enquete Perinatale Francaise Study G. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-61.
30. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15:1074-5.
31. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782-9.
32. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-603.